8 completed, 1 unknown. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Unknown 1 |
Follow Amisulpride: new trials by email Literature Review of Amisulpride trials Research Report on Amisulpride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd. - Bioequivalence, Schizophrenia | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 100 | 2023-09-20 | 2023-10-04 |
| Effects of a Single Dose of Amisulpride on Functional Brain Changes Amisulpride Pill, Placebo - Major Depressive Disorder | Phase 1 | Completed | Simone Grimm | 127 | 2022-05-17 | 2023-11-24 |
| PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment Amisulpride IV, Amisulpride Oral Tablet - Renal Disease, End Stage | Phase 1 | Completed | Acacia Pharma Ltd | 12 | 2021-06-03 | 2021-12-13 |
| Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics SEP-363856, Amisulpride, Placebo - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 105 | 2014-03-01 | 2024-06-26 |
| Thorough QT Study of Intravenous Amisulpride APD421 5 mg, APD421 40 mg, Moxifloxacin - Healthy | Phase 1 | Completed | Acacia Pharma Ltd | 40 | 2013-11-01 | 2018-11-29 |
| An Investigation of Early Life Stress and Depression Amisulpride, Placebo - Major Depressive Disorder (MDD), History of Childhood Sexual Abuse (CSA) | Phase 1 | Completed | Mclean Hospital | 153 | 2013-08-01 | 2025-05-07 |
| Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study Cannabidiol CR, Cannabidiol, Amisulpride - Schizophrenia | Phase 1 | Completed | Central Institute of Mental Health, Mannheim | 74 | 2013-01-01 | 2018-03-08 |
| The Effects of Dopamine on Reward Processing amisulpride, placebo - Major Depressive Disorder (MDD) | Phase 1 | Completed | Mclean Hospital | 159 | 2012-02-01 | 2018-04-27 |
| Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors Pramipexole, Amisulpride - Obsessive-Compulsive Disorder | Phase 1 | Completed | GlaxoSmithKline | 52 | 2006-08-01 | 2014-09-15 |
Depressive Disorder, Major (3) · Schizophrenia (3) · Depression (1) · Kidney Failure, Chronic (1) · Obsessive-Compulsive Disorder (1)
Acacia Pharma Ltd (2) · Mclean Hospital (2) · Central Institute of Mental Health, Mannheim (1) · GlaxoSmithKline (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Simone Grimm (1) · The Affiliated Hospital of Qingdao University (1)
United States (3) · Germany (2) · United Kingdom (2) · China (1)
Christian Keicher, Dr. med. (1) · Diego A Pizzagalli, PhD (1) · Diego Pizzagalli, PhD (1) · Gabriel Fox, MB BChir (1) · Gabriel Fox, MD (1)
PMID 31784354, PMID 28942738, PMID 37550314, PMID 38012795
2008 (1), R01MH068376 (1), R01MH095809 (1)